🔗 Share this article

An underground economy for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.

Experimental Drug Gaining Traction Online

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing properties. Viewers are urged to message these accounts privately for source information, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Additionally, a flourishing trade exists on Telegram, where groups with numerous of participants share “before and after” images, administration instructions and claims of next-day British shipping. Sellers promote the drug there before redirecting buyers to other platforms for purchases.

Learning About Retatrutide

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could help individuals reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed online as the next Ozempic.

Healthcare Professionals Express Worries

Nevertheless, physicians and pharmacists have warned that the sale of what is still an unapproved medication in the UK is a cause for concern and could lead to individuals administering products of unknown origin.

Some experts stated the popularity for the experimental drug could be linked to the rising price of licensed weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several influencers try to sidestep the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and supply can still violate pharmaceutical, advertising, and customer laws, risking penalties, prosecution or prison.

Service Reaction and Content Removal

According to the social media company, the service has removed violative content and banned associated hashtags and query recommendations. The organization said it was committed to maintaining the platform secure and investing in strengthening compliance measures.

Digital Marketplace Operations

Investigations also discovered groups with up to nine thousand participants marketing the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up groups with thousands of members, populated with photos of slimming results, glowing reviews and step-by-step guides for preparing or injecting at home.

After moments of joining one group, a seller shared contact information, where the majority of purchases occur. The seller sent an instruction manual and promised shipping within 48 hours. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one asked about body mass, medical conditions or previous experience.

Product Details and Costs

Within these groups, posts display black plastic packages with postal service labels, claiming to contain new batches. One message stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors typically sold at £160 for 20mg. When questioned how much time a pen should last, vendors give contradictory answers varying between a several days to “depends on your body”.

Service Oversight and Security Actions

A representative for Telegram stated it actively moderated harmful content on its service including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are injecting substances they can’t verify. Even if the science behind retatrutide is sound, these online versions may not include what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor linked the increase in interest to recent cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using online platforms. But fake injections are highly dangerous. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.

Her team has previously seen individuals harmed by personal administration from unverified suppliers. “We understand the frustration, but buying from messaging apps or communication platforms is taking chances with your well-being,” stated the doctor. “These materials could be contaminated or improperly measured.”

Producer Position

A representative from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this time no one can market [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet approved … may subject users to possibly serious medical dangers”.